Loading...
•
Mar 31
Tango Therapeutics Q1 2025 Earnings Report
Tango Therapeutics reported a larger net loss on slightly lower revenue, while extending its cash runway into 2027 by reducing preclinical spending.
Key Takeaways
Tango Therapeutics posted a net loss of $39.9 million for Q1 2025 with revenues slightly down year-over-year. The company reduced R&D spend on discontinued programs, helping extend its cash runway to Q1 2027, and continues to advance its lead PRMT5 programs.
Net loss widened to $39.9 million from $37.9 million a year earlier.
Revenue dropped to $5.4 million due to reduced collaboration activity.
Cash position stood at $216.7 million, sufficient to fund operations into Q1 2027.
Focus shifted to TNG462 and PRMT5 programs while cutting costs in preclinical pipeline.
Tango Therapeutics
Tango Therapeutics
Forward Guidance
Tango Therapeutics plans to prioritize its PRMT5 pipeline with major clinical updates and new trial initiations expected in the second half of 2025.
Positive Outlook
- Cash runway extended into Q1 2027
- TNG462 Phase 1/2 update expected in 2H 2025
- Enrollment for TNG462 + RAS(ON) combo trial to start in Q2 2025
- TNG456 Phase 1/2 trial enrollment also starting in Q2 2025
- TNG260 clinical update expected in 2H 2025
Challenges Ahead
- Reduced collaboration revenue due to lower research activity
- Increased G&A costs impacting net loss
- Net loss widened compared to Q1 2024
- Preclinical pipeline deprioritized, reducing future diversity
- Combination studies with standard-of-care regimens deferred